Immix Biopharma (IMMX) Shares Outstanding (Weighted Average) (2020 - 2026)

Immix Biopharma has disclosed Shares Outstanding (Weighted Average) across 7 years of filings, most recently posting $55.4 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $55.4 million, up 86.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $55.4 million (up 86.42% YoY), and the FY2025 annual result was $33.0 million, up 16.55% from the prior year.
• Shares Outstanding (Weighted Average) came in at $55.4 million for Q1 2026 at Immix Biopharma, up from $33.0 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $55.4 million in Q1 2026 to a low of $13.8 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $23.4 million (2024), against an average of $23.9 million.
• Across the five-year window, Shares Outstanding (Weighted Average) soared 311.3% in 2022 and rose 0.48% in 2023, its largest moves.
• Immix Biopharma's Shares Outstanding (Weighted Average) stood at $13.9 million in 2022, then gained by 24.87% to $17.3 million in 2023, then jumped by 63.11% to $28.3 million in 2024, then gained by 16.55% to $33.0 million in 2025, then soared by 67.96% to $55.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $55.4 million (Q1 2026), $33.0 million (Q4 2025), and $31.9 million (Q3 2025), per Business Quant data.